• Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1.

      Tungen, Jørn Eivind; Gerstmann, Lisa; Vik, Anders; De Matteis, Roberta; Colas, Romain Alexandre; Dalli, Jesmond; Chiang, Nan; Serhan, Charles Nicholas; Kalesse, Markus; Hansen, Trond Vidar; et al. (Wiley, 2018-12-20)
      New drugs that can resolve inflammation without immunosuppressive effects are at the medicinal chemistry frontier. Pro-resolving endogenously formed small molecules, that is, the resolvins, are excellent candidates displaying such bioactions. The first total synthesis of the specialized pro-resolving mediator RvD1n-3 DPA has been achieved using the underutilized sp3 -sp3 Negishi cross coupling reaction and an alkyne hydrosilylation-protodesilylation protocol. Biological evaluations revealed that this novel mediator displays low nanomolar pro-resolving properties and potently activates the human DRV1/GPR32 receptor. As such, this endogenous natural product is a lead compound for the development of novel immunoresolvents.